The table below shows UNITED THERAPEUTICS Corp's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$781.50M
$799.50M
$798.60M
$794.40M
$748.90M
$714.90M
Cost of revenue
$133.40M
$100.90M
$87.60M
$92.50M
$83.10M
$77.80M
Gross profit
$648.10M
$698.60M
$711.00M
$701.90M
$665.80M
$637.10M
R&D
$138.20M
$127.50M
$134.00M
$149.00M
$103.50M
$139.60M
UTHR annual revenue (10-K history)
UNITED THERAPEUTICS Corp reported annual revenue of $3.18B for fiscal year 2025. That is up 10.6% from $2.88B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.60B (FY 2016) to $3.18B. Figures come from the company's audited annual reports as filed with the SEC.